questionsmedicales.fr
Facteurs biologiques
Protéines et peptides de signalisation intercellulaire
Cytokines
Chimiokines
Chimiokines CC
Protéines chimioattractives monocytaires
Chimiokine CCL2
Chimiokine CCL2 : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Chimiokine CCL2 : Questions médicales les plus fréquentes",
"headline": "Chimiokine CCL2 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Chimiokine CCL2 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-26",
"dateModified": "2025-02-20",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Chimiokine CCL2"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Protéines chimioattractives monocytaires",
"url": "https://questionsmedicales.fr/mesh/D018945",
"about": {
"@type": "MedicalCondition",
"name": "Protéines chimioattractives monocytaires",
"code": {
"@type": "MedicalCode",
"code": "D018945",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.374.200.110.990"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Chimiokine CCL2",
"alternateName": "Chemokine CCL2",
"code": {
"@type": "MedicalCode",
"code": "D018932",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Nidhi Joshi",
"url": "https://questionsmedicales.fr/author/Nidhi%20Joshi",
"affiliation": {
"@type": "Organization",
"name": "Department of Biotechnology, Indian Institute of Technology Roorkee, Roorkee 247667, Uttarakhand, India."
}
},
{
"@type": "Person",
"name": "Krishna Mohan Poluri",
"url": "https://questionsmedicales.fr/author/Krishna%20Mohan%20Poluri",
"affiliation": {
"@type": "Organization",
"name": "Department of Biotechnology, Indian Institute of Technology Roorkee, Roorkee 247667, Uttarakhand, India. Electronic address: krishfbt@iitr.ac.in."
}
},
{
"@type": "Person",
"name": "Nupur Nagar",
"url": "https://questionsmedicales.fr/author/Nupur%20Nagar",
"affiliation": {
"@type": "Organization",
"name": "Department of Biotechnology, Indian Institute of Technology Roorkee, Roorkee 247667, Uttarakhand, India."
}
},
{
"@type": "Person",
"name": "Élora Midavaine",
"url": "https://questionsmedicales.fr/author/%C3%89lora%20Midavaine",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Institut de pharmacologie de Sherbrooke, Université de Sherbrooke, 3001, 12e Avenue Nord, Sherbrooke, QC, Canada. elora.midavaine@usherbrooke.ca."
}
},
{
"@type": "Person",
"name": "Philippe Sarret",
"url": "https://questionsmedicales.fr/author/Philippe%20Sarret",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Institut de pharmacologie de Sherbrooke, Université de Sherbrooke, 3001, 12e Avenue Nord, Sherbrooke, QC, Canada."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Prostate and metastasis-directed focal therapy in prostate cancer: hype or hope?",
"datePublished": "2023-02-03",
"url": "https://questionsmedicales.fr/article/36718727",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/14737140.2023.2171991"
}
},
{
"@type": "ScholarlyArticle",
"name": "The combined role of MRI prostate and prostate health index in improving detection of significant prostate cancer in a screening population of Chinese men.",
"datePublished": "2023-05-02",
"url": "https://questionsmedicales.fr/article/37534902",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.4103/aja20239"
}
},
{
"@type": "ScholarlyArticle",
"name": "Simultaneous thulium laser resection of the prostate and transperineal prostate biopsy in clinically diagnosed metastatic prostate cancer with bladder outlet obstruction.",
"datePublished": "2023-08-18",
"url": "https://questionsmedicales.fr/article/37596454",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s10103-023-03848-5"
}
},
{
"@type": "ScholarlyArticle",
"name": "Staging Prostate Cancer with",
"datePublished": "2023-04-28",
"url": "https://questionsmedicales.fr/article/37116912",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.2967/jnumed.122.265371"
}
},
{
"@type": "ScholarlyArticle",
"name": "Prostate MRI Qualification:",
"datePublished": "2022-05-11",
"url": "https://questionsmedicales.fr/article/35544372",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.2214/AJR.22.27615"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Facteurs biologiques",
"item": "https://questionsmedicales.fr/mesh/D001685"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines et peptides de signalisation intercellulaire",
"item": "https://questionsmedicales.fr/mesh/D036341"
},
{
"@type": "ListItem",
"position": 4,
"name": "Cytokines",
"item": "https://questionsmedicales.fr/mesh/D016207"
},
{
"@type": "ListItem",
"position": 5,
"name": "Chimiokines",
"item": "https://questionsmedicales.fr/mesh/D018925"
},
{
"@type": "ListItem",
"position": 6,
"name": "Chimiokines CC",
"item": "https://questionsmedicales.fr/mesh/D019742"
},
{
"@type": "ListItem",
"position": 7,
"name": "Protéines chimioattractives monocytaires",
"item": "https://questionsmedicales.fr/mesh/D018945"
},
{
"@type": "ListItem",
"position": 8,
"name": "Chimiokine CCL2",
"item": "https://questionsmedicales.fr/mesh/D018932"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Chimiokine CCL2 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Chimiokine CCL2",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-07",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Chimiokine CCL2",
"description": "Comment mesurer les niveaux de CCL2 ?\nQuels tests sont utilisés pour évaluer l'inflammation ?\nCCL2 est-il un biomarqueur de maladies ?\nComment CCL2 est-il lié à la maladie cardiovasculaire ?\nPeut-on détecter CCL2 dans le liquide céphalorachidien ?",
"url": "https://questionsmedicales.fr/mesh/D018932?mesh_terms=Prostatic+Neoplasms&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Chimiokine CCL2",
"description": "Quels symptômes sont associés à des niveaux élevés de CCL2 ?\nCCL2 est-il lié à des symptômes neurologiques ?\nComment CCL2 affecte-t-il le système immunitaire ?\nDes niveaux de CCL2 peuvent-ils causer de la douleur ?\nCCL2 est-il impliqué dans des maladies respiratoires ?",
"url": "https://questionsmedicales.fr/mesh/D018932?mesh_terms=Prostatic+Neoplasms&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Chimiokine CCL2",
"description": "Comment réduire les niveaux de CCL2 ?\nLe stress influence-t-il CCL2 ?\nY a-t-il des aliments qui réduisent CCL2 ?\nL'exercice physique affecte-t-il CCL2 ?\nLa qualité du sommeil influence-t-elle CCL2 ?",
"url": "https://questionsmedicales.fr/mesh/D018932?mesh_terms=Prostatic+Neoplasms&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Chimiokine CCL2",
"description": "Quels traitements ciblent CCL2 ?\nCCL2 peut-il être une cible pour des thérapies anticancéreuses ?\nComment les anti-inflammatoires affectent-ils CCL2 ?\nY a-t-il des traitements naturels pour CCL2 ?\nLes corticostéroïdes influencent-ils CCL2 ?",
"url": "https://questionsmedicales.fr/mesh/D018932?mesh_terms=Prostatic+Neoplasms&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Chimiokine CCL2",
"description": "Quelles complications sont liées à CCL2 ?\nCCL2 est-il impliqué dans des maladies neurodégénératives ?\nComment CCL2 affecte-t-il le diabète ?\nY a-t-il des risques d'infection liés à CCL2 ?\nCCL2 est-il lié à des troubles auto-immuns ?",
"url": "https://questionsmedicales.fr/mesh/D018932?mesh_terms=Prostatic+Neoplasms&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Chimiokine CCL2",
"description": "Quels facteurs augmentent CCL2 ?\nL'âge influence-t-il les niveaux de CCL2 ?\nLes infections chroniques affectent-elles CCL2 ?\nLe régime alimentaire influence-t-il CCL2 ?\nLe manque d'exercice est-il un facteur de risque pour CCL2 ?",
"url": "https://questionsmedicales.fr/mesh/D018932?mesh_terms=Prostatic+Neoplasms&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment mesurer les niveaux de CCL2 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les niveaux de CCL2 peuvent être mesurés par des tests ELISA dans le sérum ou les tissus."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'inflammation ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests comme la CRP et la mesure de CCL2 aident à évaluer l'inflammation."
}
},
{
"@type": "Question",
"name": "CCL2 est-il un biomarqueur de maladies ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, CCL2 est un biomarqueur potentiel pour des maladies inflammatoires et auto-immunes."
}
},
{
"@type": "Question",
"name": "Comment CCL2 est-il lié à la maladie cardiovasculaire ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux élevés de CCL2 sont associés à l'inflammation dans les maladies cardiovasculaires."
}
},
{
"@type": "Question",
"name": "Peut-on détecter CCL2 dans le liquide céphalorachidien ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, CCL2 peut être détecté dans le liquide céphalorachidien, indiquant une inflammation neurologique."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont associés à des niveaux élevés de CCL2 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux élevés de CCL2 peuvent entraîner des symptômes d'inflammation comme douleur et fatigue."
}
},
{
"@type": "Question",
"name": "CCL2 est-il lié à des symptômes neurologiques ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, CCL2 est impliqué dans des symptômes neurologiques dans des maladies comme la sclérose en plaques."
}
},
{
"@type": "Question",
"name": "Comment CCL2 affecte-t-il le système immunitaire ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "CCL2 attire les monocytes et les lymphocytes, influençant la réponse immunitaire."
}
},
{
"@type": "Question",
"name": "Des niveaux de CCL2 peuvent-ils causer de la douleur ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, CCL2 peut contribuer à la douleur en favorisant l'inflammation dans les tissus."
}
},
{
"@type": "Question",
"name": "CCL2 est-il impliqué dans des maladies respiratoires ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, CCL2 est associé à des maladies respiratoires comme l'asthme et la BPCO."
}
},
{
"@type": "Question",
"name": "Comment réduire les niveaux de CCL2 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Adopter un mode de vie sain, avec une alimentation équilibrée et de l'exercice, peut aider."
}
},
{
"@type": "Question",
"name": "Le stress influence-t-il CCL2 ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut augmenter les niveaux de CCL2 et l'inflammation."
}
},
{
"@type": "Question",
"name": "Y a-t-il des aliments qui réduisent CCL2 ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des aliments riches en antioxydants, comme les baies, peuvent aider à réduire CCL2."
}
},
{
"@type": "Question",
"name": "L'exercice physique affecte-t-il CCL2 ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut diminuer les niveaux de CCL2 et améliorer la santé globale."
}
},
{
"@type": "Question",
"name": "La qualité du sommeil influence-t-elle CCL2 ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un sommeil de qualité peut réduire l'inflammation et les niveaux de CCL2 dans le corps."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent CCL2 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des inhibiteurs de CCL2 sont en développement pour traiter des maladies inflammatoires."
}
},
{
"@type": "Question",
"name": "CCL2 peut-il être une cible pour des thérapies anticancéreuses ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, cibler CCL2 pourrait aider à réduire l'infiltration tumorale et l'inflammation."
}
},
{
"@type": "Question",
"name": "Comment les anti-inflammatoires affectent-ils CCL2 ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les anti-inflammatoires peuvent réduire les niveaux de CCL2 et atténuer l'inflammation."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements naturels pour CCL2 ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines plantes médicinales peuvent moduler les niveaux de CCL2, mais des études sont nécessaires."
}
},
{
"@type": "Question",
"name": "Les corticostéroïdes influencent-ils CCL2 ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les corticostéroïdes peuvent réduire l'expression de CCL2 dans les tissus inflammés."
}
},
{
"@type": "Question",
"name": "Quelles complications sont liées à CCL2 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux élevés de CCL2 peuvent entraîner des complications dans les maladies cardiovasculaires."
}
},
{
"@type": "Question",
"name": "CCL2 est-il impliqué dans des maladies neurodégénératives ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, CCL2 est associé à des complications dans des maladies comme Alzheimer et Parkinson."
}
},
{
"@type": "Question",
"name": "Comment CCL2 affecte-t-il le diabète ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "CCL2 peut contribuer à l'inflammation et aux complications associées au diabète."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques d'infection liés à CCL2 ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux élevés de CCL2 peuvent augmenter le risque d'infections en favorisant l'inflammation."
}
},
{
"@type": "Question",
"name": "CCL2 est-il lié à des troubles auto-immuns ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, CCL2 est impliqué dans des complications de troubles auto-immuns comme la polyarthrite."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent CCL2 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le tabagisme, l'obésité et le stress sont des facteurs de risque augmentant CCL2."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il les niveaux de CCL2 ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les niveaux de CCL2 tendent à augmenter avec l'âge, contribuant à l'inflammation."
}
},
{
"@type": "Question",
"name": "Les infections chroniques affectent-elles CCL2 ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les infections chroniques peuvent augmenter les niveaux de CCL2 dans le corps."
}
},
{
"@type": "Question",
"name": "Le régime alimentaire influence-t-il CCL2 ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un régime riche en graisses saturées peut augmenter les niveaux de CCL2 et l'inflammation."
}
},
{
"@type": "Question",
"name": "Le manque d'exercice est-il un facteur de risque pour CCL2 ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le manque d'exercice peut contribuer à des niveaux élevés de CCL2 et à l'inflammation."
}
}
]
}
]
}
The paradigm of focal therapy's role in metastatic patients is being challenged by evolving attitudes and emerging data. At the current time, specifically regarding prostate cancer, does the evidence ...
We searched the literature via PubMed, MEDLINE, and Embase for studies from 2014 to the present addressing focal therapy with non-palliative intent in metastatic prostate cancer patients, emphasizing ...
Current evidence is strongest, and in our opinion practice-changing, for prostate-directed RT in de novo metastatic patients with low metastatic burden. Metastasis-directed therapy with SBRT is consis...
Using prostate-specific antigen (PSA) for prostate cancer (PCa) screening led to overinvestigation and overdiagnosis of indolent PCa. We aimed to investigate the value of prostate health index (PHI) a...
Metastatic prostate cancer (mPCa) patients complicated with bladder outlet obstruction (BOO) are often referred to a urologist. Androgen deprivation therapy (ADT) combined with indwelling catheter usu...
Although prostate-specific membrane antigen (PSMA) PET/CT has been shown valuable for staging biopsy-proven [B(+)] high-risk prostate cancer, elderly patients are occasionally referred for PSMA PET/CT...
Prostate MRI is now established as a first-line investigation for individuals presenting with suspected localized or locally advanced prostate cancer. Successful delivery of the MRI-directed pathway f...
Prostate cancer has a long disease history and a wide variety and uncertainty in individual patients' clinical progress. In recent years, we have seen a revolutionary advance in both prostate cancer p...
There is a clinical need to identify patients with an elevated PSA who would benefit from prostate biopsy due to the presence of clinically significant prostate cancer (CSCaP). We have previously repo...
To further develop and adapt the MiCheck® Prostate test so it can be performed using a standard clinical chemistry analyzer and characterize its performance using the MiCheck-01 clinical trial sample ...
About 358 patient samples from the MiCheck-01 US clinical trial were used for the development of the MiCheck® Prostate test. These consisted of 46 controls, 137 non-CaP, 62 non-CSCaP, and 113 CSCaP....
Serum analyte concentrations for cellular growth factors were determined using custom-made Luminex-based R&D Systems multi-analyte kits. Analytes that can also be measured using standard chemistry ana...
Logistic regression modeling with Monte Carlo cross-validation was used to identify Human Epidydimal Protein 4 (HE4) as an analyte able to significantly improve the algorithm specificity at 95% sensit...
The MiCheck® logistic regression model was developed and consisted of PSA, %free PSA, DRE, and HE4. The model differentiated clinically significant cancer from no cancer or not-clinically significant ...
The MiCheck® Prostate test identifies clinically significant prostate cancer with high sensitivity and negative predictive value (NPV). It can be performed in a clinical laboratory using a Roche Cobas...
Prostate health index (PHI) and, more recently, Proclarix have been proposed as serum biomarkers for prostate cancer (PCa). In this study, we aimed to evaluate Proclarix and PHI for predicting clinica...
Proclarix and PHI were measured using samples of 344 men from two different centers. All patients underwent prostate biopsy, and among those, 188 men with PCa on biopsy had an additional radical prost...
The cohort median age and PSA were 65 (interquartile range [IQR]: 60-71) and 5.6 (IQR: 4.3-7.2) ng/ml, respectively. CsPCa was diagnosed in 161 (47%) men based on the RP specimen. ROC analysis showed ...
Results of this study show that both Proclarix and PHI accurately detect the presence of csPCa. The model combining Proclarix and PHI revealed the synergistic effect and improved the diagnostic perfor...
Transperineal (TP) multiparametric magnetic resonance imaging (mpMRI)-targeted biopsy (TBx) has been shown to detect more clinically significant (cs) prostate cancer (PCa) than standard template biops...
We identified all men who with suspicious lesions on mpMRI and underwent TP TBx (3-core) and concomitant SBx (20-core) in our single hospital from September 2019 to February 2021. Clinical, MRI and bi...
Three hundred and one (n = 301) men were included. The median prostate volume by MRI was 45 ml. The patients were divided by prostate volume into three groups: ≤30ml group (19.9%), >30 to ≤45 ml group...
Our data suggest that performing TBx with limited additional cores may potentially achieve the same csPCa detection rate as the combined SBx and TBx in smaller prostates....
We sought to determine whether two soluble forms with different size of mtDNA are linked to prostatic inflammation, and whether they discriminate prostate cancer (PCa) from inflammatory prostatic cond...
Histopathologically diagnosed prostatitis, PCa and benign prostatic hyperplasia patients (n = 93) were enrolled in this study and they were categorized as with and without prostate inflammation. Quant...
The urine mtDNA-79 and mtDNA-230 were significantly increased in patients with prostate inflammation compared with those in without inflammation. Here, 79-bp fragment of apoptotic origin was significa...
Our results demonstrate that shorter cf-mtDNA fragment size in particular, increase in the presence of prostate inflammation in post-prostatic massage urine but both fragments could never improve seru...